Back to Search
Start Over
Will the 7-valent pneumococcal vaccine have a similar impact on all invasive pneumococcal infections in children in Germany as in the Kaiser Permanente Trial?
- Source :
-
European journal of pediatrics [Eur J Pediatr] 2002 Dec; Vol. 161 Suppl 2, pp. S140-3. Date of Electronic Publication: 2002 Oct 02. - Publication Year :
- 2002
-
Abstract
- Unlabelled: A 7-valent pneumococcal conjugate (7-vPc) vaccine was shown to be highly effective in California preventing 89.1% of all invasive pneumococcal infections (IPI) regardless of serotype. There is concern whether a similar effectiveness will be attained in Germany where 52% of all IPI in children <16 years were caused by the serotypes in the vaccine. The study was based on prospective, active surveillance of IPI in German children aged <16 years during 1997 to 2000. Coverage by the 7-vPc vaccine (with and without 6A) in unvaccinated children in the Kaiser Permanente Trial (KPT) was compared to the coverage in German children in the same age period as in the KPT. The proportion of potentially preventable cases was estimated both for unvaccinated children in the KPT and for Germany by multiplication of the coverage rates with the vaccine efficacy estimate from the KPT (intention to treat analysis). Successful serotyping could be attained for 38.3% of the 1,743 German IPI cases. In the age period from 7 to 43 months concerned in the KPT, the proportion of cases with serotypes covered by the 7-vPc vaccine (+6A) was 91% (95% CI 80%-97%) in the unvaccinated children in the KPT compared to 76% (95% CI 71%-80%) in Germany. The respective estimates for the number of potentially preventable IPI cases were 85% (95% CI 75%-91%) in the KPT compared to 71% (95% CI 67%-75%) in Germany.<br />Conclusion: Age specific serotype coverage rates have to be considered for extrapolation of the Kaiser Permanente Trial to the German situation. Although 14% lower than in the Kaiser Permanente Trial, 71% of potentially preventable cases of invasive pneumococcal infection still predict an excellent effectiveness for the 7-valent pneumococcal conjugate vaccine in Germany.
- Subjects :
- Adolescent
Age Factors
Child
Child Welfare
Child, Preschool
Evidence-Based Medicine
Germany epidemiology
Heptavalent Pneumococcal Conjugate Vaccine
Humans
Infant
Infant Welfare
Infant, Newborn
Meningitis, Pneumococcal drug therapy
Population Surveillance
Prospective Studies
Serotyping
Streptococcus pneumoniae classification
Treatment Outcome
Meningococcal Vaccines therapeutic use
Pneumococcal Infections drug therapy
Pneumococcal Vaccines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0340-6199
- Volume :
- 161 Suppl 2
- Database :
- MEDLINE
- Journal :
- European journal of pediatrics
- Publication Type :
- Academic Journal
- Accession number :
- 12494261
- Full Text :
- https://doi.org/10.1007/s00431-002-1067-9